Search

everythingexperts & clinicslearnresearchcommunity

for

Search:↓

Both baricitinib and tofacitinib effectively reduce alopecia areata severity, with tofacitinib showing more improvement over longer use.

PRMT5 inhibitors effectively fight adenoid cystic carcinoma in salivary glands.

Rapamycin reduces skin cell growth and tumor development by affecting cell signaling in mice.

Decreasing MIG6 can increase the movement and invasiveness of MEK-inhibited mutant NRAS melanoma, particularly when stimulated by EGF.

Mirvetuximab soravtansine improves quality of life and reduces symptoms more than standard chemotherapy in ovarian cancer patients.

Tofacitinib regrew hair in a man with total hair loss but raised cytokine levels, needing more research on possible side effects.

JAK inhibitors help regrow hair in alopecia areata, but their long-term safety is still unclear.

Testosterone reduces knee movement, while flutamide and finasteride increase it.

Chemoprevention can significantly lower cancer risks and needs more research and collaboration.

Erlotinib can cause persistent excessive hair growth.

ONO-3403 effectively reduces mouse skin tumor growth without side effects.

Tofacitinib was more effective than apremilast in treating hair loss in a mouse model of alopecia areata.

Baricitinib is effective for severe alopecia areata with manageable side effects, mainly upper respiratory infections.

BMS-470539 reduces skin fibrosis and inflammation.

The combination of tadalafil and finasteride improves urinary symptoms and erectile function in men with enlarged prostates.

Kidney cancer cells without folliculin are more sensitive to radiation due to increased self-eating cell death.

Upadacitinib effectively treated severe hair loss in a child.

Blocking mTORC1 activity with rapamycin could help increase hair pigmentation and growth, potentially reversing gray hair.

A man's hair regrew from alopecia areata after using tofacitinib and experiencing contact dermatitis from a wig device.

The treatment showed significant hair regrowth in alopecia areata patients without side effects.

PRIDE complex side effects from EGFR inhibitors can be managed without stopping treatment.

Oral tofacitinib is more effective than oral minoxidil for treating alopecia areata.

Oral JAK inhibitors effectively treat alopecia areata and are generally well-tolerated.

Tofacitinib and methotrexate successfully treated a woman's severe skin, joint, and hair loss issues.

Baricitinib shows promise for treating alopecia areata with mild side effects.

JAK inhibitors like tofacitinib may effectively treat alopecia in children without major side effects.

A rare skin reaction from cancer treatment was successfully managed with topical treatments and antihistamines.

Upadacitinib improved symptoms and hair regrowth in a teen with multiple autoimmune conditions.

Prescriptions for 5-alpha reductase inhibitors dropped significantly after the FDA's safety warning, especially for men with benign prostatic hyperplasia.